跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
TGA
/
CAELYX doxorubicin hydrochloride 20 mg/10 mL concentrated injection vial
Approved
STANDARD
CAELYX doxorubicin hydrochloride 20 mg/10 mL concentrated injection vial
Baxter Healthcare Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 29, 2025
Approval ID
d1c8bf5804e487ce
Company
Baxter Healthcare Pty Ltd
Type
Standard
Approval Details
Approval Id
d1c8bf5804e487ce
Product Name
CAELYX doxorubicin hydrochloride 20 mg/10 mL concentrated injection vial
Artg Id
60384
Artg Name
CAELYX doxorubicin hydrochloride 20 mg/10 mL concentrated injection vial
Sponsor
Baxter Healthcare Pty Ltd
Company Detail Path
/organization/baxter-healthcare-pty-ltd
Artg Date
1997-08-06
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/877eedc631056f4d391b647fe0cd698c.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/a202e961bfd01582e55dfdddb1cc9f5f.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 29, 2025
Approval ID
d1c8bf5804e487ce
Type
Standard
Back to TGA Approvals
CAELYX doxorubicin hydrochloride 20 mg/10 mL concentrated injection vial - TGA Drug Approval Details